Urine collection device

A urine collection device for females is described. It is comprised of a collection element defining a urine collection chamber and an inlet opening into the chamber and is adapted to be disposed in surrounding relation to the urethral opening of the user. A drainage conduit is connected to the collection element in communication with the chamber whereby the chamber and conduit together comprise a urine flow pathway for carrying urine generally away from the inlet. A first body of wicking material is mounted adjacent the collection element and extends at least partially into the flow pathway. The device preferably also comprise a vaginal insert element including a seal portion for preventing the entry of urine into the vagina

Patent Landscape of Helminth Vaccines and Related Technologies

Executive Summary This report focuses on patent landscape analysis of technologies related to vaccines targeting parasitic worms, also known as helminths. These technologies include methods of formulating vaccines, methods of producing of subunits, the composition of complete vaccines, and other technologies that have the potential to aid in a global response to this pathogen. The purpose of this patent landscape study was to search, identify, and categorize patent documents that are relevant to the development of vaccines that can efficiently promote the development of protective immunity against helminths. The search strategy used keywords which the team felt would be general enough to capture (or “recall”) the majority of patent documents which were directed toward vaccines against helminths. After extensive searching of patent literature databases, approximately 2847 publications were identified and collapsed to about 446 INPADOC families. Relevant patent families, almost half of the total relevant families (210 being total number of relevant families), were then identified and sorted into the categories of trematodes, cestodes, nematodes or nonspecific helminth. The 210 patent families that were divided into these four major categories were then further divided into sub categories relating to common fields of technology (e.g. DNA vaccine, vaccine formulations, methods to produce subunits) This sorting process increased the precision of the result set. The four major categories (cestodes, nematodes, trematodes, and non specific applications) as well as the overall data set of the 210 relevant family members were subjected to a range of analytics in order to extract as much information as possible from the dataset. First, patent landscape maps were generated to assess the accuracy of the sorting procedure and to reveal the relationships between the various technologies that are involved in creating an effective vaccine. Then, filings trends are analyzed for the overall dataset of the 210 relevant families as well as by the categories of trematodes, cestodes, and nematodes. The country of origin each member of the 210 relevant families was determined, and the range of distribution to other jurisdictions was assessed. Filings were also analyzed by year, by assignee. Finally, the various patent classification systems were mapped to find which particular classes tend to hold helminth vaccine-related technologies. Besides the keywords developed during the searches and the landscape map generation, the classifications represent an alternate way for further researchers to identify emerging helminth vaccine technologies. The analysis included creation of a map of keywords describing the relationship of the various technologies involved in the development of helminth vaccines. The map has regions corresponding to plasmids and other gene based technologies used in DNA vaccines for Japonicum Schistosoma. Important technologies listed on the map include the use of reverse genetics to create reassorted viruses targeted for the use in veterinary applications. Additionally, the map suggests that numerous subunits exist for use in vaccines targeting cestodes, trematodes, and nematodes. Another major finding was that the number of patent documents related to helminths being published has been steadily increasing in the last decade, as shown in the figure below. Until the early-1990s, there were only a few helminth vaccine related patent documents being published each year. The number of publications increased noticeably when TRIPS took effect, resulting in publication of patent applications. However, since 2006 the number of vaccine publications has exploded. In the years 2011 and 2012, about 23 references disclosing parasitic worm vaccine technologies were published each year. Thus, interest in developing new and more efficacious helminth vaccines has been growing in recent years. The origin of the vaccine-related inventions was also analyzed. The team determined the country in which the priority application was filed, which was taken as an indication of the country where the invention was made or where the inventors intended to practice the invention. By far, most of the relevant families originated with patent applications filed in the United States and China. Other prominent priority countries were the United Kingdom, Japan, Brazil, Australia and France. Countries with the most filings were also analyzed. Countries that were heavily targeted for patent filings included the United States, Australia, Canada, and New Zealand. Top assignees for these families were mostly large pharmaceutical companies, with the majority of patent families coming from Heska, followed by Merck & Co., Institute Pasteur, AusBiotech Biotechnology, and Biological Sciences Research Council. Lastly, the jurisdictions were inventors have sought protection for their vaccine technologies were determined, and the number of patent families filing in a given country is plotted on the world map shown (Fig. 25). The United States, Canada, Australia, Japan, New Zealand and France have the highest level of filings, followed by Germany, Brazil, India, United Kingdom and Spain. However, although there are a significant number of filings in Brazil, the remainder of Central and South America has only sparse filings. Of concern, with the exception of South Africa, few other African nations have a significant number of filings. In summary, the goal of this report is to provide a knowledge resource for making informed policy decisions and for creating strategic plans concerning the assembly of vaccines targeting highly prevalent helminth infections. The ITTI team has defined the current state of the art of technologies involved in the manufacture of helminth vaccines, and the important assignees, inventors, and countries have been identified. This document should aid in evaluating the current state of vaccines technologies targeting helminths and the potential outgrows of these technological fields. Furthermore, as this report illustrates, the steady increase in helminth patenting, expanded diversity of assignees and greater global filings, indicates that intellectual property protection does not inhibit the development of crucial innovations for this class of neglected diseases, but, on the contrary, appears to be a driver of accelerated research and development

Two-dimensional dilaton black holes

The two-dimensional CGHS model provides an interesting toy-model for the study of black hole evaporation. For this model, a quantum effective action, which incorporates Hawking radiation and backreaction, can be explicitly constructed. In this paper, we study a generalization of this effective action. In our extended model, it is possible to remove certain curvature singularities arising for the original theory. We also find that the flux of Hawking radiation is identical to that encountered in other two-dimensional models

Mechanisms for Lasing with Cold Atoms as the Gain Medium

We realize a laser with a cloud of cold rubidium atoms as gain medium, placed in a low-finesse cavity. Three different regimes of laser emission are observed corresponding respectively to Mollow, Raman and Four Wave Mixing mechanisms. We measure an output power of up to 300 $\mu$W and present the main properties of these different lasers in each regime

On Slip Bands Obtained by Tension on Aluminium Specimens

IN RECENT studies'- ' we have been able to reveal the fine structure of Slip hands : we could also, on the other hand, determine the influence of deformation hands and adjacent crystals on their structure. In the present paper our aim is to define the mutual relations existing bctwween micro-hardness and slip bands. We are also examining the influence exerted by dimensions of the specimen and state of initial perfection on the development of these slip hands during plastic deformation. To avoid any anibiguity, we are explaining below what we mean by the following phrases : "Kink band" : unhent zone consisting of two kink hands in opposite ends. "Kink band": in knee" zone of great curvature separating two unbent ,zones. "Deformation band" : kink band, kink hand in knee, secondary slip hand. "Slip line"' : intersection of the surface of the specimen and only one slip plane. "Slip band" ; grouping of parallel slip lines

The Kolmogorov-Smirnov test for the CMB

We investigate the statistics of the cosmic microwave background using the Kolmogorov-Smirnov test. We show that, when we correctly de-correlate the data, the partition function of the Kolmogorov stochasticity parameter is compatible with the Kolmogorov distribution and, contrary to previous claims, the CMB data are compatible with Gaussian fluctuations with the correlation function given by standard Lambda-CDM. We then use the Kolmogorov-Smirnov test to derive upper bounds on residual point source power in the CMB, and indicate the promise of this statistics for further datasets, especially Planck, to search for deviations from Gaussianity and for detecting point sources and Galactic foregrounds.Comment: Improved significance of the results (which remain unchanged) by using patches instead of ring segments in the analysis. Added sky maps of the Kolmogorov-parameter for original and de-correlated CMB ma

Modelling of mercury isotope separation in CP stellar atmospheres: results and problems

Formation of anomalous isotope abundances in the atmospheres of chemically peculiar (CP) stars can be explained by light-induced drift (LID). This effect is additional to the radiative acceleration and appears due to systematic asymmetry of radiative flux in partly overlapping isotopic spectral line profiles. LID causes levitation of an isotope with a red-shifted spectral line and sinking of an isotope with a blue-shifted line, generating thus diffusive separation of isotopes. We have studied diffusion of mercury as a typical well-studied isotope-rich heavy metal. Our model computations show that in mercury-rich quiescent atmospheres of CP stars LID causes levitation of the heavier mercury isotopes and sinking of the lighter ones. Precise quantitative modelling of the process of isotope separation demands very high-resolution computations and the high-precision input data, including data on hyperfine and isotopic splitting of spectral lines, adequate line profiles and impact cross-sections. Presence of microturbulence and weak stellar winds can essentially reduce the effect of radiative-driven diffusion.Comment: 8 pages, 4 figures. Manuscript accepted for publication in New Astronomy Reviews (proceedings of the 7th Serbian Conference on Spectral Line Shapes in Astrophysics, Zrenjanin, Serbia, June 15-19 2009

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.

ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization across rheumatology practices in the United States and compares whether patients initiating biosimilars remain on these treatments at least as long as new initiators of bio-originators.MethodsWe identified a cohort of patients initiating a TNFi biosimilar between January 2017 and September 2018 from an electronic health record registry containing data from 218 rheumatology practices and over 1 million rheumatology patients in the United States. We also identified a cohort of patients who initiated the bio-originator TNFi during the same period. We calculated the proportion of biosimilar prescriptions compared with other TNFi's and compared persistence on these therapies, adjusting for age, sex, diagnoses codes, and insurance type.ResultsWe identified 909 patients prescribed the biosimilar infliximab-dyyb, the only biosimilar prescribed, and 4413 patients with a new prescription for the bio-originator infliximab. Biosimilar patients tended to be older, have a diagnosis code for rheumatoid arthritis, and covered by Medicare insurance. Over the study period, biosimilar prescriptions reached a maximum of 3.5% of all TNFi prescriptions. Patients persisted on the biosimilar at least as long as the bio-originator infliximab (hazard ratio [HR] 0.83, P = 0.07).ConclusionThe uptake of biosimilars in the United States remains low despite persistence on infliximab-dyyb being similar to the infliximab bio-originator. These results add to clinical studies that should provide greater confidence to patients and physicians regarding biosimilar use